{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:16:52Z","timestamp":1784661412989,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T00:00:00Z","timestamp":1512518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hidradenitis suppurativa (<jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content>), a chronic inflammatory disease that affects apocrine gland\u2013bearing skin, has a significant impact on patients' quality of life. Estimates of the epidemiologic prevalence of <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content> are highly variable, and clinical data on disease characteristics and patient burden of disease remain limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The primary objective of this study was to determine the number of patients with <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content> attending dermatology clinics in a hospital setting in Ireland (within a 6\u2010month time period). Secondary objectives included the assessment of disease characteristics and the collection of patient responses on disease burden and work productivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was an epidemiologic, non\u2010interventional, cross\u2010sectional study across four dermatology clinics in Ireland over a 6\u2010month time period. The disease prevalence was estimated by calculating the percentage of total patients with a diagnosis of <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content> (the primary population) across the selected sites. Secondary analyses were performed using the full analysis set, which consisted of eligible adults (\u226518\u00a0years of age) from the primary population who provided informed consent. Data from these analyses are presented as descriptive summary statistics, with the use of an analysis of covariance for continuous endpoints.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content> across the four selected sites was estimated at 1.4% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 1.24\u20131.62). One hundred and fifty eligible patients comprised the full analysis set. The majority of participants were white (95.3%), female (70.0%), cigarette smokers (56.0%) and overweight or obese (body mass index \u226525\u00a0kg\/m<jats:sup>2<\/jats:sup>, 81.8%). Most patients for whom data were available presented with Hurley stage <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> (50.4%), and more than a third of the full analysis set had a relative with <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content> (34.7%). Questionnaire responses revealed a profound impact on quality of life, including diminished work productivity and various psychological comorbidities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study offers insight into the clinical features and disease burden of hidradenitis suppurativa in an Irish population.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14686","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T16:02:40Z","timestamp":1510329760000},"page":"467-473","source":"Crossref","is-referenced-by-count":59,"title":["A cross\u2010sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP)"],"prefix":"10.1111","volume":"32","author":[{"given":"E.","family":"Delany","sequence":"first","affiliation":[{"name":"AbbVie Limited Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gormley","sequence":"additional","affiliation":[{"name":"AbbVie Limited Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Dermatology St Vincent's University Hospital Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Department of Dermatology South Infirmary Victoria University Hospital Cork Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kirthi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Adelaide and Meath Hospital Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Markham","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Galway Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.\u2010M.","family":"Tobin","sequence":"additional","affiliation":[{"name":"Department of Dermatology Adelaide and Meath Hospital Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Dermatology South Infirmary Victoria University Hospital Cork Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kirby","sequence":"additional","affiliation":[{"name":"Department of Dermatology St Vincent's University Hospital Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2014.44012"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.911"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2008.00712_1.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2012.01552.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14038"},{"key":"e_1_2_6_7_1","volume-title":"Dermatologic Surgery, Principles and Practice","author":"Hurley H","year":"1989"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.08.010"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.02.013"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-12-201212180-00004"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10254.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09198.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1985.tb02037.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90321-7"},{"key":"e_1_2_6_15_1","first-page":"AB155","article-title":"Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: results from the placebo\u2010controlled portion of a phase II, randomized, double\u2010blind study","volume":"64","author":"Kimball A","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2011.571657"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.255"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.043"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000447716"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.5070\/D3223030360"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.08.052"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.22.5.367"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000018126"},{"key":"e_1_2_6_24_1","unstructured":"MRBI I.Healthy Ireland Survey 2015: Summary of Findings.2015."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000431037"},{"key":"e_1_2_6_26_1","first-page":"AB42","article-title":"Adalimumab improves health\u2010related quality of life and work productivity in patients with hidradenitis suppurativa: results from a placebo\u2010controlled phase II trial","volume":"66","author":"Mrowietz U","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_27_1","unstructured":"Trading Economics. Ireland Unemployment Rate.2016."},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14922"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:03:38Z","timestamp":1695549818000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/jdv.14686"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14686","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,6]]}}}